About Ensoma
Ensoma is a company based in Boston (United States) founded in 2019. Ensoma has raised $205 million across 3 funding rounds from investors including ARE, Mirae Asset and Takeda Pharmaceuticals. The company has 52 employees as of December 31, 2021. Ensoma has completed 1 acquisition, including Twelve Bio. Ensoma offers products and services including HSC Engineering Platform and In Vivo Treatments. Ensoma operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Boston, United States
- Employees 52 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ensoma, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$205 M (USD)
in 3 rounds
-
Latest Funding Round
$50 M (USD), Series B
May 16, 2023
-
Investors
ARE
& 19 more
-
Employee Count
52
as on Dec 31, 2021
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ensoma
Ensoma offers a comprehensive portfolio of products and services, including HSC Engineering Platform and In Vivo Treatments.
Platform for in vivo engineering of stem cells to treat diseases.
One-time therapies targeting genetic and immune disorders.
People of Ensoma
Unlock access to complete
Unlock access to complete
Funding Insights of Ensoma
Ensoma has successfully raised a total of $205M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $50 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ensoma
Ensoma has secured backing from 20 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Mirae Asset and Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A venture capital firm focused on biotechnology innovations.
|
Locked | Locked | Locked | |
|
Delos Capital is engaged in private equity and financial advisory services.
|
Locked | Locked | Locked | |
|
Investments in healthcare companies are made by SymBiosis.
|
Locked | Locked | Locked |
Investor details for Ensoma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ensoma
Ensoma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Twelve Bio.
Investment portfolio details for Ensoma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
CRISPR-Cas12a technology is applied to develop diagnostics and therapeutics.
|
Locked | Locked | 2019 | Locked |
Complete acquisition details for Ensoma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Ensoma
Detailed financials for Ensoma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ensoma Comparisons
Peer comparison for Ensoma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ensoma
Ensoma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
Detailed competitors of Ensoma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ensoma
Complete news archive for Ensoma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ensoma
Ensoma was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Ensoma is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Ensoma is a funded company, having raised a total of $205M across 3 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Ensoma is 52.
Ensoma was founded in 2019 and is based in Boston, United States. Operations focus on biotechnology, specifically in vivo modification of hematopoietic stem cells and other immune cells using engineered adenovirus vectors known as Engenious. These vectors enable delivery of genome modification technologies for treating myeloablative conditions through a single injection. Services target applications in T cells, B cells, and myeloid cells within the therapeutic sector.
Ensoma's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Ensoma offers HSC Engineering Platform and In Vivo Treatments.
Ensoma has made 1 acquisition, including Twelve Bio.
Ensoma has 20 investors. Key investors include ARE, Mirae Asset, Takeda Pharmaceuticals, Kite Pharma, and Fred Hutch.